North American study and meta-analysis evaluating performance of Bladder EpiCheck®, a FDA cleared test, in non-muscle invasive bladder cancer recurrence
Neil Fleshner, Herbert Barton Grossman, Ryan Berglund, Jason Hafron, Brant Inman, Lawrence Karsh, Kelvin Moses, Daniel Saltzstein, Anup Shah, Jonathan Wright, Johannes Alfred Witjes, Yair Lotan · 2025
Read North American study and meta-analysis evaluating performance of Bladder EpiCheck®, a FDA cleared test, in non-muscle invasive bladder cancer recurrence by Neil Fleshner, Herbert Barton Grossman, Ryan Berglund, Jason Hafron, Brant Inman, Lawrence Karsh, Kelvin Moses, Daniel Saltzstein, Anup Shah, Jonathan Wright, Johannes Alfred Witjes, Yair Lotan (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11864238.txt.
Description
Fleshner and eleven co-authors test a urine test for bladder cancer that has come back. The text is dated 2024, though the catalog lists 2025. Bladder EpiCheck reads methylation marks in urine. The team ran a blinded North American trial and pooled past studies.
In the trial, the test caught about two thirds of returns and most high-grade ones. A clear scan paired with a bad test still warned of later return. Risk ran over five times higher after a positive test. The authors back the test as an aid to watch-and-wait care. It may help space out scope checks for some patients.
Catalog record
| CREATOR | Neil Fleshner, Herbert Barton Grossman, Ryan Berglund, Jason Hafron, Brant Inman, Lawrence Karsh, Kelvin Moses, Daniel Saltzstein, Anup Shah, Jonathan Wright, Johannes Alfred Witjes, Yair Lotan |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |